ShangPharma, the contract research organisation that last October nearly tripled its research-model capacity by acquiring the assets of Charles River Laboratories’ in vivo pharmacology facility in Shanghai, has further expanded its laboratory and office space to service the growing needs of one of its largest clients, Eli Lilly.
The opening of a new facility in Shanghai coincides with the announcement that ShangPharma has signed a multi-year extension of its existing service contract with Lilly, which has made China central to its emerging-markets strategy.
That effort has included strategic collaborations with companies and academic institutions in China, including ShangPharma subsidiary Shanghai ChemExplorer Company Ltd., which has provided exclusive chemistry services to Lilly.
“Renewing our agreement to serve as a key support partner for Lilly’s discovery services is a clear indication that international pharmaceutical companies appreciate the high quality of ShangPharma’s team and the excellence of our R&D capability,” commented chief executive officer Michael Xin Hui.
The newly opened facility adds 110,000 sq ft of laboratory and office space to ShangPharma’s overall capacity, and it is “fully dedicated” to supporting Lilly’s ongoing and future projects, the company noted.